CareDx, Inc. (NASDAQ:CDNA) CFO and COO Keith Kennedy filed a Form 4 on November 9, 2026, disclosing the exercise of stock options and sale of common stock on November 5, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Kennedy acquired 52,422 shares of common stock via employee stock option exercise at a price of $29.43 per share on November 5, 2026.
  • Shares sold: Kennedy disposed of a total of 61,961 shares across eight separate sale transactions on November 5, 2026, at weighted average prices ranging from $76.5485 to $83.60 per share.
  • 10b5-1 plan: According to the filing, all sale transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Kennedy on August 6, 2026.
  • Remaining ownership: Following all reported transactions, Kennedy directly held 199,147 shares of CareDx common stock.
  • Derivative securities remaining: After the option exercise, Kennedy retained 48,229 employee stock options with an exercise price of $29.43, expiring September 12, 2034.
  • Vesting schedule: According to the filing, one-quarter of the shares subject to the exercised option vested on September 12, 2025, with 1/48th vesting monthly thereafter through September 30, 2028.

Kennedy Exercises Options and Sells CareDx Shares Under Pre-Set Trading Plan

Keith Kennedy, serving as CFO and COO of CareDx, Inc. (NASDAQ:CDNA), reported a series of transactions on November 5, 2026, in a Form 4 filed with the SEC on November 9, 2026. The filing shows Kennedy first exercised employee stock options covering 52,422 shares at an exercise price of $29.43 per share, bringing his direct beneficial ownership to 261,108 shares prior to any sales.

Kennedy then sold a total of 61,961 shares across eight tranches at weighted average prices between $76.5485 and $83.60. The filing notes that each sale tranche involved multiple transactions within specific price ranges: the largest single tranche was 28,256 shares sold at a weighted average of $76.5485, with individual prices in that tranche ranging from $76.00 to $76.99. Additional tranches covered price ranges up to $83.60 per share for the final 600-share sale. The filing states that Kennedy undertakes to provide full information on individual transaction prices within each range upon request by the issuer, any security holder, or SEC staff.

All eight sale transactions were reported as effected under a Rule 10b5-1 trading plan that Kennedy adopted on August 6, 2026, as indicated by the "X" checked on the form and confirmed in the footnotes. Following all transactions, Kennedy's direct beneficial ownership stood at 199,147 shares of CareDx common stock, and he retained 48,229 employee stock options with an exercise price of $29.43 and an expiration date of September 12, 2034.

What Was Disclosed

The filing disclosed that CareDx CFO and COO Keith Kennedy exercised 52,422 stock options at $29.43 and sold 61,961 shares on November 5, 2026, under a pre-established Rule 10b5-1 plan, leaving him with direct ownership of 199,147 shares.